Get started
Author

Owain Saunders

Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
2007 · Joachim Drevs, Patrizia Siegert, et al. · Journal of Clinical Oncology · 303
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours
2010 · Hester van Cruijsen, Emile E. Voest, et al. · European Journal of Cancer · 54
A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): Final PFS results
2008 · D. Cunningham, R. P. Wong, et al. · Journal of Clinical Oncology · 29
R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study
2020 · Rose Hart, Darren Burns, et al. · PharmacoEconomics · 15
Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)
2016 · Philippe Moreau, Katja C. Weisel, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 11
PDF
Evaluation of AZD2171, an oral, highly potent and selective VEGFR signaling inhibitor, in renal cell carcinoma (RCC): Combined results from two phase I studies
2007 · C. van Herpen, J. Drevs, et al. · Journal of Clinical Oncology · 10
A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered days 1 and 15, every four weeks in patients with advanced solid tumors.
2010 · M. E. Scheulen, K. B. Mross, et al. · Journal of Clinical Oncology · 6
Survival Analysis from the CALGB Study of Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation Adjusted for Crossover (Alliance 100104)
2018 · Philip L. McCarthy, Paul Richardson, et al. · Blood · 5
Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis
2014 · Neil Roskell, Owain Saunders, et al. · European Respiratory Journal · 4
Prm23 - Modelling Cancer Treatments in the Adjuvant Setting: a Targeted Literature Review (tlr) of Technology Appraisals (ta) of Adjuvant Therapies Submitted to the National Institute for Health and Care Excellence (nice) and a Case Study in Adjuvant Melanoma.
2018 · R Batteson, M Hemstock, et al. · Value in Health · 2
Estimating the Health State Utility of Patients with HER2– gBRCA+ Metastatic Breast Cancer Treated with Olaparib or Chemotherapy Via A Mapping Analysis of Eortc QLQ-C30 Data Collected in the Olympiad Clinical Trial
2018 · M Robson, R Hettle, et al. · Value in Health · 1
Lenalidomide for Treating Multiple Myeloma After 1 Prior Treatment; An Application of Multi-State Markov Modelling for the Extrapolation of Patient Level Survival Data
2016 · O Saunders, J Gregory, et al. · Value in Health · 1
Analyzing the relationship of response and survival in patients with refractory or relapsed and refractory multiple myeloma (RRMM) treated with pomalidomide plus low-dose dexamethasone (POM + LoDEX) in the MM-003 trial.
2015 · Katja Weisel, Philippe Moreau, et al. · Journal of Clinical Oncology · 1
496 A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered day 1 and 15 every four weeks, in patients with advanced solid tumours
2010 · M. Scheulen, K. Mross, et al. · European Journal of Cancer Supplements · 1
705 POSTER Evaluation of thyroid function in an open-label Phase I study of AZD2171 with gefitinib
2007 · E.E. Voest, H. van Cruijsen, et al. · European Journal of Cancer Supplements · 1
Pcv114 Feasibility of Using Real World Evidence to Inform Decisions on Conducting a Cost Effectiveness Analysis: an Example of Stroke Risk Reduction Therapies in Atrial Fibrillation
2019 · O. Saunders, R.L. Akehurst, et al. · Value in Health
PDF
Survival Outcomes in Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM) in the MM 003 Trial: Impact of Stable Disease (SD) as a Response to Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX)
2015 · P. Moreau, K. Weisel, et al. · Clinical Lymphoma Myeloma & Leukemia
Comparative effectiveness of Bimatoprost 0.03%/Timolol 0.5% preservative-free fixed combination for the treatment of open-angle Glaucoma and OHT; interpreting results from a large treatment Network
2015 · O. Saunders, W. Wong, et al. · Value in Health
化学的最適化を介した新規デュオカルマイシン腫瘍活性プロドラッグ抱合体CRX‐103の発見:in vitro特性化および原理の証明
2001 · NG Hp, Wu G, et al. · Clinical Cancer Research
Works count: 19
Citation count: 444
H-index: 6
I10-index: 6
Year
Topic
Type